Jun Qian

List of Publications by Year
in descending order

61	1,694	304743 22	302126 39
papers	citations	h-index	g-index

63	63	63	1989
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Panâ€cancer analysis identifies <scp>CD300</scp> molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia. Cancer Medicine, 2023, 12, 789-807.	2.8	5
2	A historical review of aggregationâ€induced emission from 2001 to 2020: A bibliometric analysis. Aggregate, 2022, 3, .	9.9	37
3	Reduced expression of lncRNA DLEU7-AS1 is a novel favorable prognostic factor in acute myeloid leukemia. Bioscience Reports, 2022, 42, .	2.4	1
4	Abnormal expression and methylation of PRR34â€AS1 are associated with adverse outcomes in acute myeloid leukemia. Cancer Medicine, 2021, 10, 5283-5296.	2.8	4
5	Aggregationâ€Induced Emission (AIE) Nanoparticlesâ€Assisted NIRâ€II Fluorescence Imagingâ€Guided Diagnosis and Surgery for Inflammatory Bowel Disease (IBD). Advanced Healthcare Materials, 2021, 10, e2101043.	7.6	50
6	A Smallâ€Molecule Diketopyrrolopyrroleâ€Based Dye for inâ€…vivo NIRâ€II Fluorescence Bioimaging. Chemistry - A European Journal, 2021, 27, 14240-14249.	3.3	11
7	Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma. International Journal of Nanomedicine, 2021, Volume 16, 6905-6922.	6.7	13
8	Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia. Bioengineered, 2021, 12, 11987-12002.	3.2	5
9	Hypomethylation of MIRâ€378 5â€™â€flanking region predicts poor survival in young patients with myelodysplastic syndrome. Molecular Genetics & Genomic Medicine, 2020, 8, e1067.	1.2	2
10	The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia. OncoImmunology, 2020, 9, 1683347.	4.6	102
11	Methylation-independent expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia. American Journal of Translational Research (discontinued), 2020, 12, 4840-4852.	0.0	0
12	Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine. Cancer Cell International, 2019, 19, 177.	4.1	7
13	DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia. Cancer Medicine, 2019, 8, 6393-6402.	2.8	5
14	Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia . OncoTargets and Therapy, 2019, Volume 12, 3295-3304.	2.0	27
15	Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. Journal of Translational Medicine, 2019, 17, 102.	4.4	18
16	Establishment and molecular characterization of decitabineâ€resistant K562 cells. Journal of Cellular and Molecular Medicine, 2019, 23, 3317-3324.	3.6	12
17	SOX7 methylation is an independent prognostic factor in myelodysplastic syndromes. Pathology Research and Practice, 2019, 215, 322-328.	2.3	2
18	Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. Journal of Cellular Physiology, 2019, 234, 9438-9446.	4.1	8

#	Article	IF	Citations
19	MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. Aging, 2019, 11, 3376-3391.	3.1	18
20	Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia. Molecular Carcinogenesis, 2018, 57, 735-744.	2.7	18
21	Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. Pathology Research and Practice, 2018, 214, 896-901.	2.3	4
22	H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clinical Epigenetics, 2018, 10, 47.	4.1	79
23	High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. Gene, 2018, 640, 79-85.	2.2	18
24	Overexpression of miRâ€216b: Prognostic and predictive value in acute myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 3274-3281.	4.1	17
25	TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 5838-5846.	4.1	23
26	Methylationâ€independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 4707-4714.	4.1	6
27	Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 6604-6614.	4.1	15
28	Hypomethylationâ€mediated H19 overexpression increases the risk of disease evolution through the association with BCRâ€ABL transcript in chronic myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 2444-2450.	4.1	25
29	Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia. Cancer Management and Research, 2018, Volume 10, 4999-5007.	1.9	26
30	Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. Journal of Translational Medicine, 2018, 16, 135.	4.4	8
31	Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies. Clinical Epigenetics, 2018, 10, 92.	4.1	27
32	Methylationâ€independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia. Journal of Cellular Physiology, 2018, 233, 9584-9593.	4.1	19
33	CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics. Clinical Chemistry and Laboratory Medicine, 2017, 55, 123-131.	2.3	20
34	Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50Âyears of age: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1853-1864.	2.5	11
35	Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia. Tumor Biology, 2017, 39, 101042831769912.	1.8	8
36	Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies. Journal of Cellular and Molecular Medicine, 2017, 21, 1468-1481.	3.6	43

#	Article	IF	Citations
37	Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia. Journal of Cancer, 2017, 8, 460-468.	2.5	9
38	Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget, 2017, 8, 41498-41507.	1.8	58
39	Biologically Inspired Polydopamine Capped Gold Nanorods for Drug Delivery and Light-Mediated Cancer Therapy. ACS Applied Materials & Interfaces, 2016, 8, 24368-24384.	8.0	162
40	DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia. Tumor Biology, 2016, 37, 8951-8960.	1.8	15
41	The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. Tumor Biology, 2016, 37, 10107-10114.	1.8	20
42	ReducedmiR-215expression predicts poor prognosis in patients with acute myeloid leukemia. Japanese Journal of Clinical Oncology, 2016, 46, 350-356.	1.3	29
43	Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0165948.	2.5	10
44	Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis. Oncotarget, 2016, 7, 47376-47386.	1.8	13
45	CEBPA methylation and mutation in myelodysplastic syndrome. Medical Oncology, 2015, 32, 192.	2.5	31
46	Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia. Biochemical and Biophysical Research Communications, 2015, 463, 1250-1256.	2.1	17
47	Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. Medical Oncology, 2015, 32, 386.	2.5	25
48	The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia. International Journal of Clinical and Experimental Pathology, 2015, 8, 4321-31.	0.5	4
49	Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. International Journal of Clinical and Experimental Pathology, 2015, 8, 5336-44.	0.5	7
50	MiR-378 Promotes the Migration of Liver Cancer Cells by Down-Regulating Fus Expression. Cellular Physiology and Biochemistry, 2014, 34, 2266-2274.	1.6	42
51	Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome. PLoS ONE, 2014, 9, e115693.	2.5	25
52	Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. International Journal of Clinical and Experimental Pathology, 2014, 7, 6832-40.	0.5	41
53	Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leukemia Research, 2013, 37, 1642-1647.	0.8	57
54	RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. Clinical Biochemistry, 2013, 46, 579-583.	1.9	60

#	Article	IF	Citations
55	Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leukemia Research, 2013, 37, 765-768.	0.8	49
56	Development of a High-Resolution Melting Analysis for the Detection of the SF3B1 Mutations. Genetic Testing and Molecular Biomarkers, 2013, 17, 342-347.	0.7	9
57	U2AF1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. PLoS ONE, 2012, 7, e45760.	2.5	75
58	IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Annals of Hematology, 2012, 91, 519-525.	1.8	96
59	Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. PLoS ONE, 2011, 6, e26906.	2.5	110
60	Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. British Journal of Haematology, 2011, 154, 153-155.	2.5	18
61	Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clinical Biochemistry, 2011, 44, 779-783.	1.9	17